Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation

Am J Hematol. 2019 Feb;94(2):E50-E53. doi: 10.1002/ajh.25362. Epub 2018 Dec 13.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, Mantle-Cell / mortality
  • Lymphoma, Mantle-Cell / therapy*
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Remission Induction / methods
  • Rituximab / therapeutic use*
  • Survival Analysis
  • Transplantation, Autologous

Substances

  • Rituximab